• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Eris Lifesciences Q2 net up 35 per cent at Rs 93.14 cr

expressbpdNovember 20, 2017

Tag: Eris , LifeSciences

Consolidated total income of the company also rose to Rs 255.68 crore

Drug firm Eris Lifesciences has reported a 34.51 per cent rise in its consolidated net profit to Rs 93.14 crore for the second quarter ended September 30. The company had posted a net profit of Rs 69.24 crore for the corresponding period of the previous fiscal, Eris Lifesciences said in a filing to BSE. Consolidated total income of the company also rose to Rs 255.68 crore for the quarter under consideration as against Rs 208.08 crore for the same period a year ago.

Previous:Statement by FDA Commissioner Scott Gottlieb, M.D., on efforts to address impact of IV fluid shortag

Next:Strides Shasun divests India brand business to Eris Lifesciences for Rs 500 cr

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Eris Lifesciences Q2 net up 35 per cent at Rs 93.14 cr | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

BG-80D Seris High-efficient Film Coating Machine Of Spraying

BG-80D Seris High-efficient Film Coating Machine Of Spraying
Radix Sileris Extarct

Radix Sileris Extarct
Rhizoma Dryopteris P.E

Rhizoma Dryopteris P.E
Iberis amara Extract Powder

Iberis amara Extract Powder
Halal Adiantum capillus veneris Extract Powder10:1

Halal Adiantum capillus veneris Extract Powder10:1
ginger powder Zingiber officinale Rosc powder gingembre powder rhizoma zingiberis recens powder

ginger powder Zingiber officinale Rosc powder gingembre powder rhizoma zingiberis recens powder
Rhizoma Dryopteris Extract

Rhizoma Dryopteris Extract
Barberry Extract Powder/Berberis Vulgaris

Barberry Extract Powder/Berberis Vulgaris
Low Maq Coptis Chinensis Berberis Aristata Extract HCL 633-65-8 Berberine Hydrochloride Powder

Low Maq Coptis Chinensis Berberis Aristata Extract HCL 633-65-8 Berberine Hydrochloride Powder
Primula veris root Extract Powder

Primula veris root Extract Powder

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service